Key Points

Iovance's Q1 revenue was sharply lower than expected. The company blamed the miss on lower production capacity due to annual maintenance at its cell therapy facility. However, Iovance's full-year revenue guidance cut hints at a deeper problem. 10 stocks we like better than Iovance Biotherapeutics ›

Shares of Iovance Biotherapeutics(NASDAQ: IOVA) were crashing 46.6% lower as of 10:40 a.m. ET on Friday. The huge decline came after the drugmaker announced its first-quarter results before the market opened.

Iovance reported Q1 revenue of $49.3 million, $43.6 million of which came from its advanced melanoma drug, Amtagvi. Although this result reflected tremendous growth from the $715,000 in revenue recorded in the prior-year period, it was much lower than the average analysts' revenue estimate of $82.4 million. Iovance also lowered its full-year revenue guidance to between $250 million and $300 million, a sharp reduction from its previous outlook of revenue between $450 million and $475 million.

How concerning is Iovance's big Q1 miss?

Iovance interim president and CEO Frederick Vogt blamed the lower-than-expected Q1 revenue on "a significant reduction in capacity during the annual scheduled maintenance at the Iovance Cell Therapy Center (iCTC)." He said that infusion volume should rebound in Q2.

Should investors not be concerned about Iovance's big Q1 miss with this simple explanation? Maybe not as much as the stock's steep plunge reflects. However, the company's full-year revenue guidance cut hints that the problem goes deeper than a temporary capacity issue. Iovance's Q1 sales were roughly $33 million below Wall Street expectations, but its revised full-year outlook is nearly $188 million lower than the previous forecast.Image source: Getty Images.

Is Iovance stock a buy on the sell-off?

Despite legitimate concerns following Iovance's surprising Q1 results, I think the stock is a good pick for aggressive investors to buy on the sell-off. There's still significant commercial potential for Amtagvi in melanoma. The drug has tremendous opportunities in treating other types of solid tumors, too.

Iovance's management team seems to be learning lessons the hard way in appreciating the challenges of launching a new cell therapy. However, that doesn't negate the long-term prospects of this beaten-down biotech stock.

Should you invest $1,000 in Iovance Biotherapeutics right now?

Before you buy stock in Iovance Biotherapeutics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Iovance Biotherapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Story Continues

Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $617,181!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $719,371!*

Now, it’s worth notingStock Advisor’s total average return is909% — a market-crushing outperformance compared to163%for the S&P 500. Don’t miss out on the latest top 10 list, available when you joinStock Advisor.

See the 10 stocks »

*Stock Advisor returns as of May 5, 2025

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy.

Why Iovance Biotherapeutics Stock Is Crashing Today was originally published by The Motley Fool

View Comments